Comparing tolerability of olanzapine in schizophrenia and affective disorders: A meta-analysis

Drug Safety

Volumn 35, Issue 10, 2012, Pages 819-836

  Moteshafi, Hoda ^a,b   Zhornitsky, Simon ^a,b   Brunelle, Sarah ^a   Stip, Emmanuel ^a,b  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b CENTRE DE RECHERCHE FERNAND SEGUIN   (Canada)

Author keywords

Affective disorders; Bipolar disorders; Meta analysis; Metabolic syndrome; Olanzapine; Schizophrenia

Indexed keywords

ANTIPARKINSON AGENT; CHOLESTEROL; GLUCOSE; OLANZAPINE; TRIACYLGLYCEROL;

ADULT DISEASE; AGE; AKATHISIA; BIPOLAR DISORDER; CHOLESTEROL BLOOD LEVEL; DOSE RESPONSE; DRUG INDUSTRY; DRUG SAFETY; DRUG TOLERABILITY; FUNDING; GLUCOSE BLOOD LEVEL; HUMAN; META ANALYSIS; MONOTHERAPY; OUTCOME ASSESSMENT; PARKINSONISM; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCHIZOPHRENIA; SEX RATIO; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; FEMALE; HUMANS; MALE; MOOD DISORDERS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA; SEX FACTORS; TREATMENT OUTCOME;

EID: 84865494044     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/11631510-000000000-00000     Document Type: Review

References (95)

1. Zhornitsky S, Potvin S, Moteshafi H, et al. Dose-response and comparative efficacy and tolerability of quetiapine across psychiatric disorders: a systematic review of the placebo-controlled monotherapy and add-on trials. Int Clin Psychopharmacol 2011 Jul; 26 (4): 183-92
2. Tohen M, Sanger TM, McElroy SL, et al. Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group. Am J Psychiatry 1999 May; 156 (5): 702-9
3. Tohen M, Jacobs TG, Feldman PD. Onset of action of antipsychotics in the treatment of mania. Bipolar Disord 2000 Sep; 2 (3 Pt 2): 261-8
4. Keck Jr PE. Bipolar depression: a new role for atypical antipsychotics? Bipolar Disord 2005; 7 Suppl. 4: 34-40
5. Bhana N, Perry CM. Olanzapine: a review of its use in the treatment of bipolar I disorder. CNS Drugs 2001; 15 (11): 871-904
6. Frampton JE. Olanzapine long-acting injection: a review of its use in the treatment of schizophrenia. Drugs 2010 Dec 3; 70 (17): 2289-313
7. Parsons B, Allison DB, Loebel A, et al. Weight effects associated with antipsychotics: a comprehensive database analysis. Schizophr Res 2009 May; 110 (1-3): 103-10
8. L'Italien GJ, Casey DE, Kan HJ, et al. Comparison of metabolic syndrome incidence among schizophrenia patients treated with aripiprazole versus olanzapine or placebo. J Clin Psychiatry 2007 Oct; 68 (10): 1510-6
9. Pramyothin P, Khaodhiar L. Metabolic syndrome with the atypical antipsychotics. Curr Opin Endocrinol Diabetes Obes 2010 Oct; 17 (5): 460-6
10. Fagiolini A, Frank E, Scott JA, et al. Metabolic syndrome in bipolar disorder: findings from the Bipolar Disorder Center for Pennsylvanians. Bipolar Disord 2005 Oct; 7 (5): 424-30
11. Rummel-Kluge C, Komossa K, Schwarz S, et al. Head-tohead comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res 2010 Nov; 123 (2-3): 225-33
12. Fleischhacker WW, Cetkovich-Bakmas M, De Hert M, et al. Comorbid somatic illnesses in patients with severe mental disorders: clinical, policy, and research challenges. J Clin Psychiatry 2008 Apr; 69 (4): 514-9
13. van Winkel R, De Hert M, Wampers M, et al. Major changes in glucose metabolism, including new-onset diabetes, within 3 months after initiation of or switch to atypical antipsychotic medication in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2008 Mar; 69 (3): 472-9
14. Laursen TM, Munk-Olsen T, Agerbo E, et al. Somatic hospital contacts, invasive cardiac procedures, and mortality from heart disease in patients with severe mental disorder. Arch Gen Psychiatry 2009 Jul; 66 (7): 713-20
15. Colton CW, Manderscheid RW. Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Prev Chronic Dis 2006 Apr; 3 (2): A42
16. Cavazzoni PA, Berg PH, Kryzhanovskaya LA, et al. Comparison of treatment-emergent extrapyramidal symptoms in patients with bipolar mania or schizophrenia during olanzapine clinical trials. J Clin Psychiatry 2006 Jan; 67 (1): 107-13
17. Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009 Jan 3; 373 (9657): 31-41
18. Miller CH, Mohr F, Umbricht D, et al. The prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone, and conventional an-tipsychotics. J Clin Psychiatry 1998 Feb; 59 (2): 69-75
19. Kane JM, Fleischhacker WW, Hansen L, et al. Akathisia: an updated review focusing on second-generation antipsy-chotics. J Clin Psychiatry 2009 May; 70 (5): 627-43
20. Kane JM. Tardive dyskinesia rates with atypical antipsychotics in adults: prevalence and incidence. J Clin Psychiatry 2004; 65 Suppl. 9: 16-20
21. Rummel-Kluge C, Komossa K, Schwarz S, et al. Secondgeneration antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons. Schizophr Bull 2010 May 31; 38 (1): 167-77
22. Muscettola G, Barbato G, Pampallona S, et al. Extrapyramidal syndromes in neuroleptic-treated patients: prevalence, risk factors, and association with tardive dyski-nesia. J Clin Psychopharmacol 1999 Jun; 19 (3): 203-8
23. Tenback DE, van Harten PN, Slooff CJ, et al. Evidence that early extrapyramidal symptoms predict later tardive dys-kinesia: a prospective analysis of 10,000 patients in the European Schizophrenia Outpatient Health Outcomes (SOHO) study. Am J Psychiatry 2006 Aug; 163 (8): 1438-40
24. Nasrallah HA, Churchill CM, Hamdan-Allan GA. Higher frequency of neuroleptic-induced dystonia in mania than in schizophrenia. Am J Psychiatry 1988 Nov; 145 (11): 1455-6
25. Stahl SM, Mignon L, Meyer JM. Which comes first: atypical antipsychotic treatment or cardiometabolic risk? Acta Psychiatr Scand 2009; 119 (3): 171-9
26. van Winkel R, van Os J, Celic I, et al. Psychiatric diagnosis as an independent risk factor for metabolic disturbances: results from a comprehensive, naturalistic screening program. J Clin Psychiatry 2008 Aug; 69 (8): 1319-27
27. Ryan MC, Collins P, Thakore JH. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry 2003 Feb; 160 (2): 284-9
28. Spelman LM, Walsh PI, Sharifi N, et al. Impaired glucose tolerance in first-episode drug-naive patients with schizophrenia. Diabet Med 2007 May; 24 (5): 481-5
29. Venkatasubramanian G, Chittiprol S, Neelakantachar N, et al. Insulin and insulin-like growth factor-1 abnormalities in antipsychotic-naive schizophrenia. Am J Psychiatry 2007 Oct; 164 (10): 1557-60
30. Zhang ZJ, Yao ZJ, Liu W, et al. Effects of antipsychotics on fat deposition and changes in leptin and insulin levels: magnetic resonance imaging study of previously untreated people with schizophrenia. Br J Psychiatry 2004 Jan; 184: 58-62
31. Arranz B, Rosel P, Ramirez N, et al. Insulin resistance and increased leptin concentrations in noncompliant schizophrenia patients but not in antipsychotic-naive first-episode schizophrenia patients. J Clin Psychiatry 2004 Oct; 65 (10): 1335-42
32. Huang J, Perlis RH, Lee PH, et al. Cross-disorder genomewide analysis of schizophrenia, bipolar disorder, and depression. Am J Psychiatry 2010 Oct; 167 (10): 1254-63
33. Peerbooms OL, van Os J, Drukker M, et al. Meta-analysis of MTHFR gene variants in schizophrenia, bipolar disorder and unipolar depressive disorder: evidence for a common genetic vulnerability? Brain Behav Immun 2011; 25 (8): 1530-43
34. Purcell SM, Wray NR, Stone JL, et al. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 2009 Aug 6; 460 (7256): 748-52
35. Borenstein M, Rothstein H. Comprehensive meta-analysis: a computer program for research synthesis. Englewood (NJ): Biostat, 1999
36. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986 Sep; 7 (3): 177-88
37. Alvarez E, Ciudad A, Olivares JM, et al. A randomized, 1-year follow-up study of olanzapine and risperidone in the treatment of negative symptoms in outpatients with schizophrenia. J Clin Psychopharmacol 2006 Jun; 26 (3): 238-49
38. Beasley Jr CM, Sanger T, Satterlee W, et al. Olanzapine versus placebo: results of a double-blind, fixed-dose olan-zapine trial. Psychopharmacology (Berl) 1996 Mar; 124 (1-2): 159-67
39. Bhowmick S, Hazra A, Ghosh M. Amisulpride versus olanzapine in the treatment of schizophrenia in Indian patients: randomized controlled trial. Aust N Z J Psychiatry 2010 Mar; 44 (3): 237-42
40. Bitter I, Dossenbach MR, Brook S, et al. Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2004 Jan; 28 (1): 173-80
41. Breier A, Berg PH, Thakore JH, et al. Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia. Am J Psychiatry 2005 Oct; 162 (10): 1879-87
42. Chan HY, Chang CJ, Chiang SC, et al. A randomised controlled study of risperidone and olanzapine for schizophrenic patients with neuroleptic-induced acute dystonia or parkinsonism. J Psychopharmacol 2010 Jan; 24 (1): 91-8
43. Dollfus S, Olivier V, Chabot B, et al. Olanzapine versus risperidone in the treatment of post-psychotic depression in schizophrenic patients. Schizophr Res 2005 Oct 15; 78 (2-3): 157-9
44. Kane JM, Osuntokun O, Kryzhanovskaya LA, et al. A 28-week, randomized, double-blind study of olanzapine versus aripiprazole in the treatment of schizophrenia. J Clin Psychiatry 2009 Apr; 70 (4): 572-81
45. Lecrubier Y, Quintin P, Bouhassira M, et al. The treatment of negative symptoms and deficit states of chronic schizophrenia: olanzapine compared to amisulpride and placebo in a 6-month double-blind controlled clinical trial. Acta Psychiatr Scand 2006 Nov; 114 (5): 319-27
46. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005 Sep 22; 353 (12): 1209-23
47. McIntyre RS, Cohen M, Zhao J, et al. A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states. Bipolar Disord 2009 Nov; 11 (7): 673-86
48. McIntyre RS, Cohen M, Zhao J, et al. Asenapine versus olanzapine in acute mania: a double-blind extension study. Bipolar Disord 2009 Dec; 11 (8): 815-26
49. McIntyre RS, Cohen M, Zhao J, et al. Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebo-controlled trial. J Affect Dis-ord 2010 Apr; 122 (1-2): 27-38
50. McIntyre RS, Cohen M, Zhao J, et al. Asenapine for longterm treatment of bipolar disorder: a double-blind 40-week extension study. J Affect Disord 2010 Nov; 126 (3): 358-65
51. McQuade RD, Stock E, Marcus R, et al. A comparison of weight change during treatment with olanzapine or ar-ipiprazole: results from a randomized, double-blind study. J Clin Psychiatry 2004; 65 Suppl. 18: 47-56
52. Riedel M, Muller N, Spellmann I, et al. Efficacy of olanzapine versus quetiapine on cognitive dysfunctions in patients with an acute episode of schizophrenia. Eur Arch Psychiatry Clin Neurosci 2007 Oct; 257 (7): 402-12
53. Saddichha S, Manjunatha N, Ameen S, et al. Effect of olanzapine, risperidone, and haloperidol treatmentonweight and body mass index in first-episode schizophrenia patients in India: a randomized, double-blind, controlled, prospective study. J Clin Psychiatry 2007 Nov; 68 (11): 1793-8
54. Sanger TM, Tohen M, Vieta E, et al. Olanzapine in the acute treatment of bipolar I disorder with a history of rapid cycling. J Affect Disord 2003 Jan; 73 (1-2): 155-61
55. Sirota P, Pannet I, Koren A, et al. Quetiapine versus olanzapine for the treatment of negative symptoms in patients with schizophrenia. Hum Psychopharmacol 2006 Jun; 21 (4): 227-34
56. Tohen M, Calabrese JR, Sachs GS, et al. Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine. Am J Psychiatry 2006 Feb; 163 (2): 247-56
57. Tohen M, Goldberg JF, Gonzalez-Pinto Arrillaga AM, et al. A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania. Arch Gen Psychiatry 2003 Dec; 60 (12): 1218-26
58. Tohen M, Jacobs TG, Grundy SL, et al. Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group. Arch Gen Psychiatry 2000 Sep; 57 (9): 841-9
59. Tohen M, Sutton VK, Calabrese JR, et al. Maintenance of response following stabilization of mixed index episodes with olanzapine monotherapy in a randomized, double-blind, placebo-controlled study of bipolar 1 disorder. J Affect Disord 2009 Jul; 116 (1-2): 43-50
60. Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003 Nov; 60 (11): 1079-88
61. Tohen M, Vieta E, Goodwin GM, et al. Olanzapine versus divalproex versus placebo in the treatment of mild to moderate mania: a randomized, 12-week, double-blind study. J Clin Psychiatry 2008 Nov; 69 (11): 1776-89
62. Vanelle JM, Douki S. A double-blind randomised comparative trial of amisulpride versus olanzapine for 2 months in the treatment of subjects with schizophrenia and co-morbid depression. Eur Psychiatry 2006 Dec; 21 (8): 523-30
63. Wu RR, Zhao JP, Liu ZN, et al. Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia. Psycho-pharmacology (Berl) 2006 Jul; 186 (4): 572-8
64. Janssen-Cilag International NV. Prospective randomized open-label 6-month head-to-head trial to compare metabolic effects of paliperidone ER and olanzapine in subjects with schizophrenia [ClinicalTrials.gov identifier NCT00645099]. US National Institutes of Health, Clin-icalTrials.gov [online]. Available from URL: http://www. clinicaltrials.gov [Accessed 2011 May 18]
65. Eli Lilly and Company. A randomized, open-label study comparing the effects of olanzapine pamoate depot with oral olanzapine ontreatment outcomesinoutpatients with schizophrenia [ClinicalTrials.gov identifier NCT00320489]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2010 Oct 25]
66. Eli Lilly and Company. Efficacy and safety of olanzapine in the treatment of patients with bipolar I disorder, depressed: a randomized, double-blind comparison with placebo [ClinicalTrials.gov identifier NCT00510146]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2011 Apr 26]
67. Schering-Plough. A multicenter, double-blind, flexible-dose, 6-month trial comparing the efficacy and safety of asena-pine with olanzapine in stable subjects with predominant, persistent negative symptoms of schizophrenia [Clinical Trials.gov identifier NCT00145496]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2010 Apr 8]
68. Eli Lilly and Company. Placebo-and haloperidol-controlled double-blind trial of olanzapine in patients with manic or mixed episode of bipolar I disorder [ClinicalTrials.gov identifier NCT00129220]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www. clinicaltrials.gov [Accessed 2010 Dec 10]
69. Henderson DC, Cagliero E, Copeland PM, et al. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch Gen Psychiatry 2005 Jan; 62 (1): 19-28
70. Newcomer JW, Haupt DW, Fucetola R, et al. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry 2002 Apr; 59 (4): 337-45
71. Bond DJ, Kauer-Sant'Anna M, Lam RW, et al. Weight gain, obesity, and metabolic indices following a first manic episode: prospective 12-month data from the Systematic Treatment Optimization Program for Early Mania (STOP-EM). J Affect Disord 2010 Jul; 124 (1-2): 108-17
72. De Hert M, Dobbelaere M, Sheridan EM, et al. Metabolic and endocrine adverse effects of second-generation anti-psychotics in children and adolescents: a systematic review of randomized, placebo controlled trials and guidelines for clinical practice. Eur Psychiatry 2011 Apr; 26 (3): 144-58
73. Peuskens J, De Hert M, Mortimer A. Metabolic control in patients with schizophrenia treated with amisulpride or olanzapine. Int Clin Psychopharmacol 2007 May; 22 (3): 145-52
74. Allison DB, Mentore JL, Heo M, et al. Antipsychoticinduced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999 Nov; 156 (11): 1686-96
75. Czobor P, Volavka J, Sheitman B, et al. Antipsychoticinduced weight gain and therapeutic response: a differential association. J Clin Psychopharmacol 2002 Jun; 22 (3): 244-51
76. Haddad P. Weight change with atypical antipsychotics in the treatment of schizophrenia. J Psychopharmacol 2005 Nov; 19 (6 Suppl.): 16-27
77. Reynolds GP, Yao Z, Zhang X, et al. Pharmacogenetics of treatment in first-episode schizophrenia: D3 and 5-HT2C receptor polymorphisms separately associate with positive and negative symptom response. Eur Neuropsycho-pharmacol 2005 Mar; 15 (2): 143-51
78. Correll CU, Lencz T, Malhotra AK. Antipsychotic drugs and obesity. Trends Mol Med 2011; 17: 97-107
79. De Hert M, Detraux J, Van Winkel R, et al. Metabolic and cardiovascular adverse effects associated with anti-psychotic drugs. Nat Rev Endocrinol 2011 Oct; 8 (2): 114-26
80. Nakamura M, Nagamine T. Severe hyperglycemia induced by olanzapine was improved with a recovery of insulin secretion after switching to risperidone and introducing insulin therapy. Intern Med 2010; 49 (23): 2635-7
81. Nasrallah HA. Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry 2008 Jan; 13 (1): 27-35
82. Bai YM, Chen TT, Liou YJ, et al. Association between HTR2C polymorphisms and metabolic syndrome in patients with schizophrenia treated with atypical antipsy-chotics. Schizophr Res 2011 Feb; 125 (2-3): 179-86
83. Gunes A, Melkersson KI, Scordo MG, et al. Association between HTR2C and HTR2A polymorphisms and metabolic abnormalities in patients treated with olanzapine or clozapine. J Clin Psychopharmacol 2009 Feb; 29 (1): 65-8
84. Melkersson KI, Gunes A, Dahl ML. Impact of serotonin receptor 2A gene haplotypes on C-peptide levels in cloz-apine-and olanzapine-treated patients. Hum Psycho-pharmacol 2010 Jun; 25 (4): 347-52
85. Casey DE. Dyslipidemia and atypical antipsychotic drugs. J Clin Psychiatry 2004; 65 Suppl. 18: 27-35
86. Chaggar PS, Shaw SM, Williams SG. Effect of antipsychotic mmedications on glucose and lipid levels. J Clin Pharmacol 2011; 51 (5): 631-8
87. Meyer JM. Novel antipsychotics and severe hyperlipidemia. J Clin Psychopharmacol 2001 Aug; 21 (4): 369-74
88. Albaugh VL, Judson JG, She P, et al. Olanzapine promotes fat accumulation in male rats by decreasing physical activity, repartitioning energy and increasing adipose tissue lipogenesis while impairing lipolysis. Mol Psychiatry 2011 May; 16 (5): 569-81
89. Wampers M, Hanssens L, van Winkel R, et al. Differential effectsof olanzapine and risperidone on plasma adiponectin levels over time: results from a 3-month prospective open-label study. Eur Neuropsychopharmacol 2012; 22 (1): 17-26
90. Carlson CD, Cavazzoni PA, Berg PH, et al. An integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: comparisons with placebo, haloperidol, ris-peridone, or clozapine. J Clin Psychiatry 2003 Aug; 64 (8): 898-906
91. Gao K, Kemp DE, Ganocy SJ, et al. Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review. J Clin Psychopharmacol 2008 Apr; 28 (2): 203-9
92. Taylor VH, McIntyre RS, Remington G, et al. Beyond pharmacotherapy: understanding the links between obesity and chronic mental illness. Can J Psychiatry 2012 Jan; 57 (1): 5-12
93. Regenold WT, Thapar RK, Marano C, et al. Increased prevalence of type 2 diabetes mellitus among psychiatric inpatients with bipolar I affective and schizoaffective disorders independent of psychotropic drug use. J Affect Disord 2002; 70: 19-26
94. Cacabelos R, Hashimoto R, Takeda M. Pharmacogenomics of antipsychotics efficacy for schizophrenia. Psychiatry Clin Neurosci 2011; 65: 3-19
95. Liou YJ, Bai YM, Lin E, et al. Gene-gene interactions of the INSIG1 and INSIG2 in metabolic syndrome in schizophrenic patients treated with atypical antipsychotics. Pharmacogenomics J 2012 Feb; 12 (1): 54-61